This review summarizes the role of contemporary antiplatelet and anticoagulant agents in the treatment of acute coronary syndromes.
Updates synthesis of antiplatelet and anticoagulant strategies in ACS; leaves open optimal regimens pending new randomized data.
Antiplatelet and anticoagulant drugs are the mainstay of treatment of acute coronary syndrome (ACS). The last 30 years have seen the development of various agents, a deeper understanding of the pathobiology of this disease, and an evolution in its treatment. We review the role of contemporary agents in ACS and highlight key clinical trials of these agents.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: